OBJECTIVE： To provide theoretic basis for the design and synthesis of novel high-activity biaryl aminothiazine β-amyloid precursor protein cleaving enzyme 1 （BACE1） inhibitor， the research and development of new AD therapy drugs. METHODS： Totally 41 molecules of biaryl aminothiazine BACE1 inhibitors were selected. By SYBYL-X 2.0 software package， CoMFA and CoMSIA method were used to construct 3D-QSAR model of derivatized compounds. Surflex-dock molecular docking was applied to analyze binding mode of the compounds with BACE1. RESULTS： The q2 value of 3D-QSAR model established by CoMFA and CoMSIA method  were all higher than 0.5， indicating good predictability. The established three dimensional contour plots could manifest the effect of substituents at different sites on activity of compounds. Surflex-dock analysis showed that biaryl aminothiazine and amino acid residues as ASP80， ASP276 and TYR246 in BACE1 had a key effect on hydrogen bonds. CONCLUSIONS： 3D-QSAR model established on the basis of biaryl aminothiazine derivatized compounds show good  predictability， which provides guidance for the structure optimization of the compound. TYR246 may be another potential active functional residue of biaryl aminothiazine inhibitor compound molecule combined with BACE1. Through 3D-QSAR analysis and molecular docking，new biaryl aminothiazine BACE1 inhibitor can be designed and synthesized so as to research and develop new drugs for AD.